CLINICAL_TRIALS
trial_result
· 2020-11-24
Clinical Trial Update: A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL [Phase 1, Phase 2]
Summary
Phase 1/2 trial of de-immunized DI-Leu16-IL2 for B-cell non-Hodgkin lymphoma; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alopexx Oncology, LLC | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-11-24